Gainers
- Portage Biotech (NASDAQ:PRTG) shares moved upwards by 105.9% to $9.7 during Friday's regular session. The company's market cap stands at $15.9 million.
- Lexicon Pharmaceuticals (NASDAQ:LXRX) shares rose 78.39% to $0.62. The company's market cap stands at $224.1 million.
- DBV Technologies (NASDAQ:DBVT) stock rose 40.92% to $5.51. The market value of their outstanding shares is at $113.0 million.
- Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 29.3% to $0.56. The market value of their outstanding shares is at $14.0 million. As per the press release, Q4 earnings came out today.
- 23andMe Holding (NASDAQ:ME) shares moved upwards by 14.24% to $0.88. The market value of their outstanding shares is at $23.5 million.
- Prelude Therapeutics (NASDAQ:PRLD) shares increased by 14.09% to $0.78. The company's market cap stands at $42.9 million.
Losers
- Sharps Technology (NASDAQ:STSS) shares decreased by 72.5% to $0.04 during Friday's regular session.
- Milestone Pharmaceuticals (NASDAQ:MIST) shares declined by 60.37% to $0.89. The market value of their outstanding shares is at $47.5 million.
- LogicMark (NASDAQ:LGMK) shares fell 51.28% to $0.02.
- Impact BioMedical (AMEX:IBO) shares decreased by 29.73% to $1.6. The company's market cap stands at $18.4 million.
- Venus Concept (NASDAQ:VERO) shares declined by 27.68% to $2.64. The company's market cap stands at $1.7 million.
- Regencell Bioscience (NASDAQ:RGC) stock fell 26.02% to $25.8. The market value of their outstanding shares is at $335.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
IBOImpact BioMedical Inc
Not Available-%
LGMKLogicMark Inc
$1.05-87.8%
LXRXLexicon Pharmaceuticals Inc
$1.42-%
MISTMilestone Pharmaceuticals Inc
$2.650.38%
PRLDPrelude Therapeutics Inc
$1.36-11.7%
RGCRegencell Bioscience Holdings Ltd
$15.76-1.50%
SNSESensei Biotherapeutics Inc
$11.9012.7%
STSSSharps Technology Inc
$2.774.14%
VEROVenus Concept Inc
$1.950.52%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
